| EDA2R–NIK signalling promotes muscle atrophy linked to cancer cachexia SN Bilgic, A Domaniku, B Toledo, S Agca, BZC Weber, DH Arabaci, ... Nature 617 (7962), 827-834, 2023 | 25 | 2023 |
| Inhibition of epidermal growth factor receptor suppresses parathyroid hormone‐related protein expression in tumours and ameliorates cancer‐associated cachexia BZC Weber, S Agca, A Domaniku, SN Bilgic, DH Arabaci, S Kir Journal of cachexia, sarcopenia and muscle 13 (3), 1582-1594, 2022 | 14 | 2022 |
| Muscle wasting: emerging pathways and potential drug targets A Domaniku, SN Bilgic, S Kir Trends in Pharmacological Sciences, 2023 | 7 | 2023 |
| Oncostatin M signaling drives cancer-associated skeletal muscle wasting A Domaniku-Waraich, S Agca, B Toledo, M Sucuoglu, SD Özen, SN Bilgic, ... Cell Reports Medicine, 2024 | 2 | 2024 |
| Activated Oncostatin M signaling drives cancer-associated skeletal muscle wasting A Domaniku, S Agca, B Toledo, SN Bilgic, AE Kashgari, S Kir BioRxiv, 2023.01. 26.525658, 2023 | 2 | 2023 |
| EDA2R/NIK signaling promotes skeletal muscle atrophy linked to cancer cachexia S Nur Bilgic, A Domaniku, B Toledo, S Agca, BZC Weber, DH Arabaci, ... bioRxiv, 2023.01. 23.525138, 2023 | 1 | 2023 |
| Tumor-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism S Agca, A Domaniku Waraich, SN Bilgic, M Sucuoglu, M Dag, SA Dogan, ... bioRxiv, 2023.10. 26.564119, 2023 | 1 | 2023 |
